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Abstract
Aims: To identify individual and general practitioner (GP) characteristics associated 
with potential over- and undertreatment of hyperglycaemia in type 2 diabetes and 
with HbA1c not being measured.
Methods: A cross-sectional study that included 10233 individuals with type 2 dia-
betes attending 282 GPs. Individuals with an HbA1c measurement during the last 15 
months were categorized as potentially overtreated if they were prescribed a sulpho-
nylurea and/or insulin when the HbA1c was less than 53 mmol/mol (7%) when aged 
over 75 years or less than 48 mmol/mol (6.5%) when aged between 65 and 75 years. 
Potential undertreatment was defined as age less than 60 years and HbA1c > 64 mmol/
mol (8.0%) or HbA1c > 69 mmol/mol (8.5%) and treated with lifestyle modification 
and/or monotherapy. We used multilevel binary and multinominal logistic regression 
models to examine associations.
Results: Overall, 4.1% were potentially overtreated, 7.8% were potentially un-
dertreated and 11% did not have HbA1c measured. Characteristics associated with 
potential overtreatment were as follows: long diabetes duration, prescribed antihy-
pertensive medication, cardiovascular disease and renal failure. Potential undertreat-
ment was associated with male gender, non-western origin and low educational level. 
Characteristics associated with not having an HbA1c measurement performed were 
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1 |  INTRODUCTION
Early, intensive and multifactorial treatment of type 2 dia-
betes reduces vascular complications.1,2 However, several 
observational studies have repeatedly confirmed subopti-
mal glycaemic control in a considerable proportion of indi-
viduals with type 2 diabetes.3–5 The GUIDANCE study with 
data from eight European countries reported that only 54% 
achieved an HbA1c target of less than 53 mmol/mol (7.0%).
3 
Individual factors like ability to adhere to recommended 
lifestyle modification and/or medication, comorbidities and 
healthcare provider and/or healthcare system factors (i.e. 
workload and health expenses) may impact the achievement 
of treatment targets and clinical outcomes.6–8
On the other hand, serious hypoglycaemia and increased 
mortality caused by intensive treatment have been increas-
ingly documented9–11 and more personalized HbA1c targets 
have been promoted.12 The Norwegian clinical Guidelines 
for Diabetes recommend an HbA1c level of approximately 53 
mmol/mol (7.0%) as a treatment target in most individuals 
with type 2 diabetes.13 The American Diabetes Association 
and the European Association for the Study of Diabetes rec-
ommend doctors to consider de-intensification when HbA1c 
is below 48mmol/mol (6.5%) or substantially below the per-
sonalized treatment target, and to consider two or more glu-
cose-lowering agents when HbA1c is 17 mmol/mol (1.5%) or 
more above the personalized treatment target.14 The concept 
of quaternary prevention, that is, actions taken to identify in-
dividuals at risk for over-medicalization and to protect them 
from medical interventions, highlights the delicate balance 
between possible benefit and harm.15
In Norway, most individuals with type 2 diabetes are 
cared for by general practitioners (GPs).13 Healthcare ser-
vices are state-funded in Norway and all citizens are en-
titled to be registered with a specific GP. In this study of 
individuals with type 2 diabetes, we aimed to identify in-
dividual and GP characteristics associated with potential 
over- and undertreatment of hyperglycaemia and charac-
teristics associated with an annual HbA1c measurement not 
being performed.
2 |  PARTICIPANTS AND METHODS
We used data from a large population-based, cross-sec-
tional survey, the ROSA 4 study (Rogaland–Oslo–Salten–
Akershus–Hordaland study), assessing the quality of type 
2 diabetes care in general practice in Norway in 2014, that 
is described in detail elsewhere.16,17 In brief, 106 practices 
with 367 GPs from urban and rural areas in 5 of Norway’s 
19 counties were invited to participate in the study, and 77 
(73%) practices with 282 (77%) GPs accepted the invitation. 
All individuals with diabetes cared for by these GPs partici-
pated in the study. Results of blood tests and prescription 
data from 2012 to 2014 were obtained from the electronic 
health records (EHRs) of all individuals aged ≥18 years with 
diabetes diagnosis. Research nurses verified the diabetes 
diagnosis and supplemented the database with information 
not captured electronically such as smoking habits, diabetes 
duration and complications by searching the EHRs using rel-
evant keywords.16,17 In total, 11 428 individuals participated 
male gender, age < 50 years and cardiovascular diseases. GP specialist status and 
GPs’ use of a Noklus diabetes application reduced the risk of not having an HbA1c 
measurement performed.
Conclusion: Potential overtreatment in elderly individuals with type 2 diabetes was 
relatively low. Nevertheless, appropriate de-intensification or intensification of treat-
ment and regular HbA1c measurement in identified subgroups is warranted.
K E Y W O R D S
family medicine, general practice, HbA1c, overtreatment, type 2 diabetes, undertreatment
What this study has found?
• According to our definitions, 4.1% of individuals 
with type 2 diabetes were potentially overtreated 
in Norway and 7.5% were potentially undertreated.
• 12% of those aged over 75 years were prescribed 
sulphonylurea and/or insulin when the HbA1c was 
less than 53 mmol/mol (7%).
• Long diabetes duration, prescribed antihyperten-
sive medication, cardiovascular disease and renal 
failure were associated with overtreatment.
• Male gender, non-western origin and low educa-
tional level were associated with undertreatment.
• GP’s workload was not associated with over- or 
undertreatment.
• Being a GP specialist and the GP’s use of Noklus 
diabetes application reduced the risk of an HbA1c 
measurement not being performed.
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in the ROSA 4 study. In the present study, we excluded indi-
viduals with other diabetes types and those with an unknown 
country of birth, leaving 10233 individuals with type 2 dia-
betes in the study (Figure 1). The study was approved by the 
Regional Ethical Committee (REK 2014/1374, REK Vest).
2.1 | Characteristics of individuals with type 
2 diabetes and general practitioners
Individual characteristics included the following: age, gen-
der, diabetes duration, smoking habits, cardiovascular 
disease (CVD) defined as stroke, angina, myocardial infarc-
tion, percutaneous coronary intervention or coronary artery 
bypass surgery. We used the most recent HbA1c value and 
the most recent prescriptions of glucose-lowering, antihy-
pertensive and lipid-lowering medication recorded between 
1st October 2013 and 31st December 2014. The most recent 
creatinine/eGFR value between 1st January 2012 and 31st 
December 2014 was also used. Information about country 
of birth and educational level was obtained from Statistics 
Norway. Ethnicity was classified as (1) Westerners (i.e. born 
in Western Europe and North America) and (2) non-western-
ers (born in non-western countries). Education was catego-
rized as follows: (1) primary school, (2) secondary school 
(including sixth form college) and (3) higher education.18
Information about GPs characteristics were collected 
using a study-specific questionnaire: age, gender, GP spe-
cialist status (i.e. having completed the specialist education 
programme for general practice), GPs use of a software tool 
(Noklus diabetes application) that lists recommended tasks in 
the annual review and allows the performance of these tasks to 
be reported to the Norwegian Diabetes Register. The number 
of individuals with type 2 diabetes cared for by each specific 
GP was captured from the GPs’ EHRs. The total number of 
individuals on the GP’s list was obtained from the Norwegian 
Health Economics Administration at the time of data collec-
tion. A GP workload factor was obtained by dividing the total 
F I G U R E  1  Flow chart of individuals with type 2 diabetes included in the study. a MODY: maturity onset diabetes of the young. b HbA1c: 
Glycated haemoglobin A1c.
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number of individuals on the GP’s list by the number of days 
per week that the GP had clinical practice.
2.2 | Outcomes
After consideration of the Norwegian Guidelines at the time 
of the study,13 recommendations from the American Diabetes 
Association and the European Association for the Study of 
Diabetes,13,14 we pragmatically defined our outcomes as poten-
tial over- or undertreatment if the following criteria were met:
Potential overtreatment: A sulphonylurea and/or insulin 
was prescribed when either HbA1c was less than 53 mmol/
mol (7%) in a patient aged over 75 years, or HbA1c was less 
than 48 mmol/mol (6.5%) in a patient aged between 65 and 
75 years.
T A B L E  1  Characteristics of individuals with type 2 diabetes by HbA1c measurement (n=10233)
Characteristics









Men 5624 (55.0) 670 (60.0) 4954 (54.3) 0.005
Age, years
Mean 64.8 (64.5, 65.0) 64.22 (63.5, 65.1) 64.8 (63.47, 65.1) 0.131
<50 1355 (13.2) 193 (17.3) 1162 (12.7) 0.820
50–59 2072 (20.2 222 (19.9) 1850 (20.3) 0.889
60–69 2998 (29.3) 294 (26.3) 2704 (29.7) 0.224
70–79 2411 (23.6) 219 (19.6) 2192 (24.0) 0.144
≥80 1397 (13.7) 189 (16.9) 1208 (13.3) 0.182
Ethnicity
Westerners 8497 (83.0) 937 (83.9) 7560 (83.0) 0.442
Non-westerners 1736 (17.0) 180 (16.1) 1736 (17.0) 0.730
Education 195 (1.9)
Primary school 3671 (36.6) 399 (36.2) 3272 (36.6) 0.876
Secondary school 4516 (45.0) 499 (45.2) 4017 (45.0) 0.933
Higher education 1851 (18.4) 205 (18.6) 1646 (18.4) 0.944
Diabetes duration, years 633 (6.2)
Mean 8.6 (8.5, 8.8) 9.2 (8.7, 9.6) 8.6 (8.4, 8.7) 0.010
<5 3214 (33.5) 327 (33.1) 2887 (33.5) 0.884
5–9 2802 (29.2) 272 (27.5) 2530 (29.4) 0.513
10–14 1855 (19.3) 191 (19.3) 1664 (19.3) 1.000
≥15 1729 (18.0) 198 (20.0) 1531 (17.2) 0.449
Current smoking 17 (0.2) 1824 (17.9) 195 (17.6) 1629 (17.9) 0.918
Medication
Glucose-lowering 6984 (68.2) 534 (48.6) 6441 (70.7) <0.001
Antihypertensive 6689 (65.4) 500 (44.8) 6189 (67.9) <0.001
Lipid-lowering 5541 (54.1) 385 (34.5) 5156 (56.6) <0.001
Cardiovascular diseasea 45 (0.4) 2801 (27.5) 310 (27.9) 2491 (27.4) 0.852
eGFR < 45 ml/min/1.73 m2 538 (5.3) 635 (6.5) 76 (9.4) 559 (6.3) 0.550
County of residence
Oslo 2526 (24.7) 219 (19.6) 2307 (25.3) 0.062
Akershus 1412 (13.8) 159 (14.2) 1253 (13.7) 0.864
Hordaland 1608 (15.7) 223 (20.0) 1385 (15.2) 0.069
Nordland 2792 (27.3) 376 (33.7) 2416 (26.5) 0.004
Rogaland 1895 (18.5) 140 (12.5) 1755 (19.3) 0.047
Chi-square tests were applied to compare group differences in proportions between those with and without HbA1c measurement. One-way between-groups ANOVA 
with post-hoc tests were applied to compare group differences in means.
aCardiovascular disease included coronary heart disease and/or stroke and/or arterial surgery. 
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Potential undertreatment: HbA1c greater than 64 mmol/
mol (8.0%) and age less than 60 years or HbA1c greater than 
69 mmol/mol (8.5%) and treated with lifestyle modification 
and/or prescribed one glucose-lowering agent only. All oth-
ers were considered to be appropriately treated.
We considered the GPs’ annual performance of HbA1c 
measurement as satisfactory if at least one HbA1c measure-
ment was recorded during the last 15 months.
2.3 | Statistical analyses
Descriptive statistics including frequencies, mean and Chi-
square tests and the one-way ANOVA tests with post-hoc 
tests were used to compare differences between the groups 
as appropriate.
Missing data (diabetes duration: 633 [6.2%], eGFR 
value: 538 [5.3%], education level: 195 [1.9%], CVD: 45 
[0.4%] and smoking status: 17 [0.2%]) were imputed to 
reduce bias in the estimates, using multiple imputation 
by chained equations, allowing for the multilevel struc-
ture of the data.19 The imputation included all variables 
in the main models (i.e. available individual data included 
in the model were used for estimation of missing value). 
We produced 10 imputed datasets. Three-level regression 
models were used to account for individuals’ data (level 
1) that were nested within GPs (level 2) who were nested 
within practices (level 3). Multilevel multinominal logistic 
regression models with the appropriate treatment group as 
reference were used to examine associations between in-
dividual and GP characteristics and potential under- and 
overtreatment. Multilevel binary logistic regression models 
with HbA1c measured or not as the dependent variable were 
run to examine the associations with individual and GP 
characteristics. Multilevel binary logistic regression mod-
els were used to estimate the proportions being prescribed 
glucose-lowering medication, adjusted for individual-level 
and GP-level characteristics. As explanatory variables, we 
included 11 individual-level variables and five GP-level 
variables in regression models.
We estimated the proportion of variance explained by 
each full model from the variance of the linear predictor 
for the fixed portion of the model and from the estimated 
random intercepts variances. Intra-cluster correlation co-
efficients were used to estimate the proportion of the out-
come or residual variations attributed to individuals, GPs 
and practices.
Sensitivity analyses included multilevel binary logistic 
regression analysis and multilevel multinomial logistic re-
gression analysis of complete cases. The significance level 
was set at < 0.01. The analyses were performed with SPSS 
Statistics 24 and StataSE 15-16.
3 |  RESULTS
Overall, 416 (4.1%) individuals with type 2 diabetes were 
potentially overtreated (all were over 65 years), 797 (7.8%) 
of all age groups were potentially undertreated (Figure 1). 
Furthermore, 1117 (11%) had no recorded annual HbA1c 
measurement. Among 1902 individuals aged over 75 years 
with recorded prescriptions for a sulphonylurea or insulin, 
231 (12%) had HbA1c < 53mmol/mol (7.0%), 108 (5.7%) had 
HbA1c < 48 mmol/mol (6.5%) while 69 (3.6%) met the crite-
ria for undertreatment (results not shown).
Characteristics of the study population stratified by 
HbA1c measurement and by treatment status are presented 
in Tables 1 and 2. Compared with individuals appropriately 
treated, those who were overtreated had longer mean dia-
betes duration (13 years vs. 8.2 years), a higher proportion 
were prescribed glucose-lowering or antihypertensive med-
ication, and had CVD or an eGFR < 45 ml/min/1.73 m2. 
Compared with individuals appropriately treated, those un-
dertreated were younger (mean age 55 years vs. 65 years), 
had longer mean diabetes duration (9.4 years vs. 8.2 years), a 
higher proportion were men (62% vs. 54%), non-westerners 
(34% vs. 16%) and were prescribed glucose-lowering med-
ication (89% vs. 67%) while a lower proportion were pre-
scribed antihypertensive medication (55% vs. 68%) (Table 
2). Compared with individuals with an HbA1c measurement, 
the group without an HbA1c measurement had a higher pro-
portion of men (60% vs. 54%), a lower proportion were 
prescribed glucose-lowering medication (49% vs. 71%), an-
ti-hypertensive medication (45% vs. 68%) and lipid-lower-
ing medication (35% vs. 57%) (Table 1). Characteristics of 
the GPs are shown in Table S1.
As the prescription pattern is an integral part in the 
definitions of over- and undertreatment, we found in the 
potentially overtreated group, 65% were prescribed sulpho-
nylurea, 32% were prescribed insulin and 2.9% were pre-
scribed both sulphonylurea and insulin. In the potentially 
undertreated group, 11% were treated with lifestyle mod-
ification only and 43% were prescribed one glucose-low-
ering agent. Prescriptions of glucose-lowering medication 
by treatment status after adjustments for confounders are 
shown in Figure 2a,b.
3.1 | Factors associated with potential 
over- and undertreatment
Characteristics associated with potential overtreatment were 
diabetes duration ≥ 15 years, prescribed antihypertensive 
medication, presence of CVD or eGFR < 45 ml/min/1.73 m2, 
whereas non-western origin and diabetes duration 5–10 years 
reduced the risk, after adjustments for all factors in Table 3.
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Characteristics associated with potential undertreatment 
were male gender, non-western origin and current smok-
ing, while characteristics reducing the odds of potential 
undertreatment were higher level of education, diabetes 
duration 5–10 years, being prescribed antihypertensive 
medication and the presence of CVD.
T A B L E  2  Characteristics of individuals with type 2 diabetes with HbA1c measured by treatment status (n=9116)
Characteristics










n=797 Pa Pb 
Men 233 (56.0) 4230 (53.5) 492 (61.7) 0.834 0.007
Age, years
Mean 76.8 (76.1, 77.5) 65.2 (64.9, 65.5) 55.1 (54.2, 56.0) <0.001 <0.001
<50 0 (0.0) 903 (11.4) 259 (32.5) <0.001
50–59 0 (0.0) 1505 (19.0) 346 (43.4) <0.001
60–69 82 (19.7) 2537 (32.1) 84 (10.5) 0.018 <0.001
70–79 186 (44.7) 1946 (24.6) 60 (7.5) <0.001 0.002
≥80 148 (35.6) 1012 (12.8) 48 (6.0) <0.001 0.164
Ethnicity
Westerners 397 (95.4) 6651 (84.2) 514 (64.5) <0.001 <0.001
Non-westerners 19 (4.6) 1252 (15.8) 283 (35.5) 0.182 <0.001
Education 180 (2.0)
Primary school 155 (37.6) 2765 (35.6) 352 (46.2) 0.613 <0.001
Secondary school 202 (49.0) 3536 (45.6) 279 (36.6) 0.346 0.004




Mean 13.2 (12.5, 14.0) 8.2 (8.1, 8.4) 9.4 (8.9, 10.0) <0.001 <0.001
<5 52 (13.5) 2614 (35.0) 222 (29.3) 0.001 0.086
5–9 76 (19.7) 2224 (29.8) 230 (30.4) 0.058 0.187
10–14 94 (24.4) 1423 (19.0) 147 (19.4) 0.199 0.906
≥15 164 (42.5) 1209 (16.2) 158 (20.9) <0.001 0.137
Current smoking 11 (0.1) 58 (10.0) 1398 (17.7) 174 (22.0) 0.130 0.165
Medication
Glucose-lowering 416 (100.0) 5316 (67.3) 708 (88.8) <0.001 <0.001
Antihypertensive 356 (85.6) 5396 (68.3) 436 (54.7) <0.001 <0.001
Lipid-lowering 262 (63.0) 4488 (56.8) 406 (50.9) 0.049 0.022
Cardiovascular 
disease
39 (0.4) 173 (41.9) 2156 (27.4) 163 (20.6) <0.001 0.059
eGFR < 45 ml/
min/1.73 m2
228 (2.5) 75 (18.2) 447 (5.8) 37 (4.9) <0.001 0.821
County of residence
Oslo 92 (22.1) 1953 (24.7) 261 (32.7) 0.571 0.005
Akershus 53 (12.7) 1099 (13.9) 101 (12.7) 0.805 0.738
Hordaland 72 (17.3) 1224 (15.5) 90 (11.3) 0.682 0.284
Nordland 115 (27.6) 2098 (26.5) 203 (25.5) 0.795 0.758
Rogaland 84 (20.2) 1529 (19.3) 142 (17.8) 0.839 0.664
Chi-square tests were applied to compare group differences in proportions.
One-way between-groups ANOVA with post-hoc tests were applied to compare group differences in means.
aDifferences between the potential overtreatment group and the appropriate treatment group. 
bDifferences between the potential undertreatment group and the appropriate treatment group. 
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3.2 | Factors associated with not having an 
HbA1c measurement performed
After adjustment for all factors in Table 4, the individual 
characteristics associated with not having an HbA1c measure-
ment performed were as follows: male gender, age less than 
50 years, diabetes duration more than 5 years and presence of 
CVD. Individual characteristics that reduced the odds of not 
having an HbA1c measurement performed were a recorded 
prescription of glucose-lowering, antihypertensive or lipid-
lowering medication, GPs specialist status and GPs use of a 
Noklus diabetes application.
3.3 | Explained variance
Differences between GPs and practices accounted for 11% 
and 15%, respectively, of the variability in potential over- and 
undertreatment. After adjustment for individual variables, 
the fixed and random effects of the full model explained 4% 
and 22% of the total variation.
Differences between GPs and practices explained 15% 
and 9% of the variability in not having an HbA1c measure-
ment performed. After adjustment, the fixed and random ef-
fects explained 3% and 21% of the variation.
4 |  DISCUSSION
Using our definitions, 4.1% of individuals with type 2 dia-
betes were potentially overtreated (12% of those aged over 
75 years), 7.8% were potentially undertreated and 11% did 
not have an annual HbA1c measurement performed. Long 
diabetes duration, prescribed antihypertensive medication, 
presence of CVD and renal failure were independently as-
sociated with potential overtreatment, whereas male gender, 
non-western origin, low education level and current smoking 
were independently associated with potential undertreatment. 
F I G U R E  2  (a) Glucose-lowering agents by treatment statusa (n=9116)b. a Potential overtreatment if prescriptions of a sulphonylurea and/
or insulin when HbA1c < 53 mmol/mol (7.0%) and age > 75 years or when HbA1c < 48 mmol/mol (6.5%) and age 65–75 years. Potential 
undertreatment if age <60 years and HbA1c > 64 mmol/mol (8.0%) or HbA1c > 69 mmol/mol (8.5%) treated with diet only or prescribed one 
glucose-lowering agent. All others are considered appropriately treated. b Missing data in the included individuals were imputed using multiple 
imputation by chained equations. Data are adjusted proportions (95%CI). Multilevel binary logistic regression models were used to estimate the 
proportions being prescribed glucose-lowering medication, adjusted for individual-level characteristics (age, gender, ethnicity, diabetes duration, 
education, current smoking, presence of cardiovascular disease, eGFR < 45 ml/min/1.73 m2, prescriptions of antihypertensive, lipid-lowering 
medication and county of residence) and GP-level characteristics (gender, specialist status, number of individuals with diabetes on GPs list, work 
load and use of Noklus diabetes application). DPP4: Dipeptidyl peptidase-4 inhibitor, SGLT2: Sodium-glucose Cotransporter-2 inhibitors, GLP1: 
Glucagon-like peptide-1 receptor agonists. Types of agents add up to > 100 % because many individuals were prescribed more than one type 
of agents. (b) Number of glucose-lowering agents by treatment statusa (n=9116)b. a Potential overtreatment if prescriptions of a sulphonylurea 
and/or insulin when HbA1c < 53 mmol/mol (7.0%) and age > 75 years or when HbA1c < 48 mmol/mol (6.5%) and age 65–75 years. Potential 
undertreatment if age < 60 years and HbA1c > 64 mmol/mol (8.0%) or HbA1c > 69 mmol/mol (8.5%) treated with diet only or prescribed one 
glucose-lowering agent. All others are considered appropriately treated.b Missing data in the included individuals were imputed using multiple 
imputation by chained equations. Data are adjusted proportions (95%CI). Multilevel binary logistic regression models were used to estimate the 
proportions being prescribed glucose-lowering medication, adjusted for individual-level characteristics (age, gender, ethnicity, diabetes duration, 
education, current smoking, presence of cardiovascular disease, eGFR < 45 ml/min/1.73 m2, prescriptions of antihypertensive, lipid-lowering 
medication and county of residence) and GP-level characteristics (gender, specialist status, number of individuals with diabetes on GPs list, work 
load and use of Noklus diabetes application).
(a) (b)
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T A B L E  3  Characteristics of individuals with type 2 diabetes and general practitioners with adjusted odd ratios for potential over- and 







OR (95% CI) P OR (95% CI) P
Men 1.14 (0.92, 1.41) 0.235 1.62 (1.38, 1.90) <0.001
Non-westerners 0.29 (0.18, 0.47) <0.001 2.57 (2.12, 3.12) <0.001
Education
Primary school 1 1
Secondary school 1.01 (0.80, 1.27) 0.939 0.72 (0.61, 0.86) <0.001
Higher education 0.81 (0.58, 1.13) 0.212 0.69 (0.56, 0.87) 0.001
Diabetes duration, years
<5 1 1
5–9 0.67 (0.54, 0.83) <0.001 0.84 (0.75, 0.96) 0.008
10–14 1.08 (0.89, 1.31) 0.451 1.13 (1.00, 1.27) 0.049
≥15 1.91 (1.59, 2.31) <0.001 1.19 (1.04, 1.36) 0.012
Current smoking 0.87 (0.65, 1.17) 0.364 1.38 (1.15, 1.67) 0.001
Medication
Antihypertensive 1.92 (1.42, 2.59) <0.001 0.66 (0.56, 0.78) <0.001
Lipid-lowering 0.85 (0.68, 1.07) 0.168 0.95 (0.80, 1.12) 0.519
Cardiovascular diseased 1.36 (1.09, 1.70) 0.007 0.70 (0.58, 0.86) <0.001
eGFR < 45 ml/min/1.73 m2 2.01 (1.51, 2.68) <0.001 1.04 (0.73, 1.49) 0.832
County of residence
Oslo 1 1
Akershus 1.04 (0.68, 1.61) 0.846 0.83 (0.60, 1.17) 0.290
Hordaland 1.04 (0.69, 1.57) 0.831 0.78 (0.55, 1.11) 0.165
Nordland 0.87 (0.61, 1.25) 0.462 1.16 (0.88, 1.54) 0.295
Rogaland 1.01 (0.68, 1.49) 0.970 0.87 (0.64, 1.18) 0.374
General practitioner (GP) characteristics
Men 1.15 (0.87, 1.52) 0.337 0.94 (0.76, 1.16) 0.539
GP specialist 0.84 (0.64, 1.11) 0.216 0.93 (0.75, 1.15) 0.509
No. individuals with diabetes on GPs list
<25 1 1
25–49 0.93 (0.67, 1.29) 0.690 1.08 (0.84, 1.38) 0.293
≥50 0.90 (0.60, 1.35) 0.510 1.05 (0.76, 1.45) 0.211
Workload factore 
<250 1 1
250–350 1.09 (0.71, 1.68) 0.660 0.85 (0.63, 1.15) 0.558
>350 1.17 (0.74, 1.86) 0.614 0.81 (0.58, 1.13) 0.748
Use of Noklus diabetes applicationf 1.05 (0.80, 1.37) 0.722 0.79 (0.63, 0.98) 0.033
Multilevel multinomial logistic regression models were used to compare the differences between the potential overtreatment group and the potential undertreatment 
group with the appropriate treatment group as reference adjusted for all variables shown in table. All models include random intercepts for practices and for general 
practitioners within practices.
aMissing data were imputed using multiple imputation by chained equations. 
bPotential overtreatment if prescriptions of a sulphonylurea and/or insulin when HbA1c < 53 mmol/mol (7.0%) and age > 75 years or when HbA1c < 48 mmol/mol 
(6.5%) and age 65–75 years. 
cPotential undertreatment if age < 60 years and HbA1c > 64 mmol/mol (8.0%) or HbA1c > 69 mmol/mol (8.5%) treated with diet only or prescribed one glucose-
lowering agent. 
dCardiovascular disease included coronary heart disease and/or stroke and/or arterial surgery. 
eThe variable reflects GPs’ workload and is obtained by dividing the total number of individuals on the GP’s list by the number of days per week the GP has clinical 
practice. 
fGeneral practitioner defined as a user of the Noklus diabetes application if used in > 40% of people with diabetes on the GP’s list. 
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Male gender, young age, long diabetes duration and presence 
of CVD increased the odds of not having an HbA1c measure-
ment performed. No GP characteristics were found to be as-
sociated with potential over- or undertreatment, whereas GP 
specialist status and GPs use of a Noklus diabetes application 
reduced the risk of not having HbA1c measured.
Our definition of overtreatment focused on individuals 
who are most vulnerable for the adverse effects of hypogly-
caemia. We found that potential overtreatment, particularly 
for those aged over 75 years was relatively low (12%), com-
pared with two recent US studies reporting that 21% and 
45% of those aged over 75 years with an HbA1c ≤ 53 mmol/
mol (7.0%) were treated with a sulphonylurea or insulin.20,21 
The latter study included individuals with type 2 diabetes re-
ceiving two or more visits at an academic diabetes centre.21 
Another US study found that 62% of elderly individuals aged 
over 65 years with an HbA1c < 53mmol/mol (7.0%) were pre-
scribed sulphonylureas or insulin.22 The GUIDANCE study, 
which included individuals with type 2 diabetes in ambula-
tory care (74% from primary care and 26% from specialist 
care), reported that 44.7% of those aged over 65 years had an 
HbA1c ≤ 53 mmol/mol (7%) and were treated with sulphony-
lureas or insulin.23 Differences in definition of overtreatment, 
the study settings and healthcare systems may partly explain 
the observed differences. Our finding of an association be-
tween the presence of CVD and overtreatment suggests that 
de-intensification of glucose-lowering medication among in-
dividuals older than 65 years ought to be considered.24
We found indications of clinical inertia with delayed initi-
ating or intensifying glucose-lowering treatment.5 Reasons for 
clinical inertia are complex and may be attributed to barriers at 
individual, GP or system level.6,25 The Norwegian state-funded 
healthcare system including financial incentives for prolonged 
consultations when appropriate, and low medical expenses for 
T A B L E  4  Characteristics of individuals with type 2 diabetes and 
general practitioners with adjusted odd ratios for not having an HbA1c 
measurement performed (n=10 233)a
Individual characteristics OR (95% CI) p
Men 1.30 (1.13, 1.51) <0.001
Age, years
<50 1.39 (1.11, 1.74) 0.005
50–59 1.16 (0.95, 1.42) 0.144
60–69 1
70–79 0.82 (0.66, 1.00) 0.055
≥80 1.03 (0.81, 1.31) 0.792
Non-westerners 0.90 (0.72, 1.12) 0.348
Education
Primary school 1
Secondary school 1.05 (0.89, 1.23) 0.573
Higher education 1.00 (0.82, 1.23) 0.971
Diabetes duration, years
<5 1
5–9 1.41 (1.18, 1.70) <0.001
10–14 1.78 (1.43, 2.20) <0.001
≥15 2.25 (1.76, 2.88) <0.001
Current smoking 1.01 (0.84, 1.21) 0.945
Medication
Glucose-lowering 0.34 (0.29, 0.40) <0.001
Antihypertensive 0.47 (0.40, 0.55) <0.001
Lipid-lowering 0.61 (0.52, 0.71) <0.001
Cardiovascular diseaseb 1.31 (1.10, 1.55) 0.003
eGFR < 45 ml/min/1.73 m2 1.35 (1.00, 1.82) 0.049
County of residence
Oslo 1
Akershus 1.69 (0.93, 3.05) 0.085
Hordaland 2.30 (1.27, 4.15) 0.006
Nordland 2.34 (1.43, 3.81) 0.001
Rogaland 1.21 (0.71, 2.07) 0.478
General practitioner (GP) 
characteristics
Men 1.21 (0.97, 1.52) 0.089
GP specialist 0.65 (0.51, 0.83) <0.001
No. individuals with diabetes 
on GPs list
<25 1
25–49 0.95 (0.69, 1.31) 0.772
≥50 0.92 (0.64, 1.34) 0.677
Workload factorc 
<250 1
250–350 1.06 (0.78, 1.45) 0.696
Individual characteristics OR (95% CI) p
>350 1.25 (0.86, 1.81) 0.248
Use of Noklus diabetes 
applicationd 
0.23 (0.18, 0.31) <0.001
Multilevel binary logistic regression models were used to compare the 
differences between those without an HbA1c measurement (n=1117) and those 
with an HbA1c measurement (n=9116) as reference. Multivariable results were 
adjusted for all variables shown in table. All models include random intercepts 
for practices and for general practitioners within practices.
aMissing data in the included individuals were imputed using multiple 
imputation by chained equations. 
bCardiovascular disease included coronary heart disease and/or stroke and/or 
arterial surgery. 
cThe variable reflects GPs’ workload and is obtained by dividing the total 
number of individuals on the GP’s list by the number of days per week the GP 
has clinical practice. 
dGeneral practitioner defined as a user of the Noklus diabetes application if used 
in > 40% of people with diabetes on the GP’s list. 
T A B L E  4  (Continued)
(Continues)
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individuals with chronical conditions, may have contributed 
to relative low level of undertreatment. However, younger in-
dividuals may benefit from more intensive glucose-lowering 
therapy as suboptimal glycaemic control increases their risk of 
complication during an expected longer life span.26 Language 
barriers and/or low health literacy among non-westerners 
might lead to a lack of adherence with prescribed medication 
and undertreatment.6,27 Similarly, lack of ability to adhere to 
recommended lifestyle modification and/or difficulties in 
coping with complex treatment regimens among those with a 
low level of educational might explain the observed associa-
tion.6,28 Our finding that male gender was associated with un-
dertreatment is in line with another study of gender differences 
in adherence to prescribed glucose-lowering medication.29 
Interestingly, only a small proportion of those aged over 75 
years were undertreated, reflecting individualization of treat-
ment in most elderly healthy individuals.24 The state-funded 
healthcare system with an average list size of 1150 persons 
per GP may explain our finding of no association between a 
GP’s workload and undertreatment while work pressure and 
time limitations in primary care were found to be a reason for 
clinical inertia in UK.6 GP specialist status had little effect on 
undertreatment. A possible explanation might be that a large 
proportion of non-specialists intend to become specialists and 
could be undergoing vocational training.
Annual HbA1c measurement and personalized treatment in-
tensification in individuals with elevated HbA1c are associated 
with better glycaemic control, although performance of HbA1c 
measurement alone does not necessarily lead to better clinical/
intermediate outcomes.30 The GUIDANCE study reported the 
overall proportion with an HbA1c measurement performed 
in the last 12 months to be 98%, with little variation between 
countries, somewhat higher than in our study.3 We have pre-
viously reported no improvements in performance of HbA1c 
measurement from 2005 to 2014,16 but for the first time, we 
have identified factors associated with not having an HbA1c 
measurement performed. In some individuals with CVD and/or 
additional co-morbidities such as terminal illness, severe stroke 
or short life expectancy, treatment of these conditions are likely 
given a higher priority during the consultation than HbA1c mea-
surement. Furthermore, some of these individuals might only 
attend secondary care or be residents at nursing homes, which 
would lead to the HbA1c test results not being registered in GP 
records during the actual period. The Noklus diabetes applica-
tion reminds GPs on recommend tasks and may have contribute 
to improve the performance of HbA1c measurement.
4.1 | Strengths and limitations
Our study has several strengths. It is a large population-based 
study conducted in general practice with high GP participa-
tion rates. The study included practices in both urban and 
rural districts and the study population is considered to be 
fairly representative for the type 2 diabetes population in 
Norway.17 Experienced research nurses verified the diabetes 
diagnosis and supplemented the database with information 
not captured electronically, thereby increasing the internal 
validity. We collected information about patients’ ethnicity 
and education levels through linkage with data from national 
registries. We obtained relevant information about 99% of 
the participating GPs from a questionnaire.
Our definitions of potential over- and undertreatment were 
essentially pragmatic decisions based on the available data, and 
we lack information about hypoglycaemic episodes and indi-
vidual lifestyle. Due to the cross-sectional design, the individ-
ual glycaemic control was based upon the most recent HbA1c 
value and the glucose-lowering medication was based on the 
most recent prescriptions, we were therefore not able to assess 
changes in prescriptions of glucose-lowering medication in re-
lation to the actual HbA1c level. Owing to these limitations, we 
were only able to compare our estimates with a limited number 
of studies. Nevertheless, we assume that GPs considered the 
most recent HbA1c value, reported hypoglycaemic episodes, 
individual health status/preferences and side effects of medica-
tion when prescribing glucose-lowering medication.
The included variables in our models explained, as ex-
pected, only a small part of the total variation. Assessment 
of the effect of individual lifestyle modification, adherence 
to prescribed medication, GPs barriers to initiation, intensi-
fication or de-intensification of glucose-lowering medication 
using a longitudinal design would have increased the valid-
ity of the study. Our findings are probably most relevant for 
counties with similar healthcare systems.
4.2 | Implications
Our results may help GPs to identify individuals with 
type 2 diabetes who may benefit from less intensive or 
more intensive glucose-lowering treatment and those who 
need tighter follow-up with regular HbA1c measurement. 
Longitudinal studies with the aims to develop strategies for 
improved management of hyperglycaemia in general prac-
tice are essential.
5 |  CONCLUSION
We found lower rates of potential overtreatment in elderly 
individuals with type 2 diabetes compared with other stud-
ies. Our results also highlight the importance of timely ini-
tiation and intensification of glucose-lowering medication in 
men, non-westerners and those with low levels of education. 
De-intensification of glucose-lowering medication should 
be considered in elderly individuals with complex disease. 
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Performance of annual HbA1c measurement in men and 
younger individuals could be improved.
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